


PRODUCT INFORMATION



Brimonidine (tartrate)

Item No. 15426

CAS Registry No.: 70359-46-5
Formal Name: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine, 2R,3R-dihydroxybutanedioate
Synonyms: AGN 190342LF, Alphagan P
MF: C₁₁H₁₀BrN₅ • C₄H₆O₆
FW: 442.2
Purity: ≥98%
UV/Vis.: λ_{max}: 244, 320 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Brimonidine (tartrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the brimonidine (tartrate) in the solvent of choice, which should be purged with an inert gas. Brimonidine (tartrate) is soluble in DMSO at a concentration of approximately 1 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of brimonidine (tartrate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of brimonidine (tartrate) in PBS (pH 7.2) is approximately 3 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Brimonidine is an agonist of α₂-adrenergic receptors (α₂-ARs; K_is = 2.7, 52, and 44 nM for α_{2A}, α_{2B}, and α_{2C}-ARs, respectively, in CHO cells).¹ It is selective for α₂-ARs over α₁-ARs (K_i = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.² It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.³ Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.

References

1. Munk, S.A., Harcourt, D.A., Arasasingham, P.N., *et al.* Synthesis and evaluation of 2-(arylamino)imidazoles as α₂-adrenergic agonists. *J. Med. Chem.* **40**(1), 18-23 (1997).
2. Sawada, K., Hiraoka, M., and Ohguro, H. Effect of antiglaucoma medicine on intraocular pressure in DBA/2J mice. *Ophthalmic Res.* **55**(4), 205-211 (2016).
3. Lee, D., Kim, K.-Y., Noh, Y.H., *et al.* Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor A in ischemic retinal injury. *PLoS One* **7**(10), e47098 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM